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EDITORIAL
Esophageal  capsule  endoscopy  and  Barrett’s  esophagus:  Where
are we  in 2013?
Cápsula  endoscópica  esofágica  y  esófago  de  Barrett:  ¿dónde  estamos  en  ell
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Capsule  endoscopy  (CE)  is  the  diagnostic  technique  of  choice
for  the  study  of  small  bowel  (SB)  pathology.  Its  high  diagnos-
tic  performance  enables  the  identiﬁcation  of  lesions  that,
even  a  few  years  ago,  were  under-diagnosed  or  discovered
late.
Initial  studies  in  the  esophagus  showed  low  cost-
effectiveness  for  capsule  endoscopy  of  the  SB,1 with  the
exception  of  the  study  by  Ramírez  et  al.2 with  string-capsule
endoscopy  using  the  PillCam® SB.  Their  study  demonstrated
a  high  cost-effectiveness,  close  to  100%,  but  it  was  not  sup-
ported  or  validated  by  further  studies.
For  this  reason,  esophageal  capsule  endoscopy  (ECE)  was
designed  speciﬁcally  for  the  study  of  that  portion  of  the
digestive  tract,  with  2  lenses  and  greater  image  capacity.
This  capsule  (initially  the  PillCam® ESO1  and  later  the  ESO2)
was  soon  proposed  as  a  useful  tool  for  the  study  of  chronic
gastroesophageal  reﬂux  disease  (GERD)  (mainly  for  the  diag-
nosis  and  follow-up  of  Barrett’s  esophagus  [BE])  and  in  the
screening  for  esophageal  varices  in  portal  hypertension.
Different  studies  carried  out  with  the  PillCam® ESO1  and
later  with  the  ESO2  in  patients  with  suspected  or  known
GERD  and  BE  have  had  these  main  disadvantages:  (1)  difﬁ-
culty  in  complete  visualization  of  the  Z  line,  improved  with
the  right  lateral  decubitus  position;  (2)  inability  to  employ
local  staining  techniques  (methylene  blue  or  Lugol’s  solu-
tion),  unlike  upper  gastrointestinal  (UGI)  endoscopy;  and
(3)  the  impossibility  to  take  biopsies  and  thereby  know  the
grade  of  dysplasia  associated  with  intestinal  metaplasia.
The  majority  of  published  case  series  comparing  the
PillCam® ESO  and  UGI  endoscopy  have  reported  a  high
speciﬁcity  and  negative  predictive  value  of  the  capsule
for  BE  screening.  However,  its  sensitivity  was  considerably
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http://dx.doi.org/10.1016/j.rgmx.2013.02.002ow,  it  had  high  interobserver  variability,  and  it  was  not
ost-effective  in  short  BE,  making  it  unrecommendable  in
hese  patients.3,4
A  later  meta-analysis  of  more  than  600  patients  with
ERD  concluded  that  ECE  had  moderate  sensitivity  and
peciﬁcity  for  diagnosing  BE  and  that  UGI  endoscopy  should
ontinue  to  be  the  gold  standard  in  these  patients.5
This  issue  of  the  Revista  de  Gastroenterología  de  México
as  published  a  study  by  Domingos  et  al.6 that  compares  ECE
ith  methylene  blue  (MB)  chromoendoscopy  following  a  reg-
lar  UGI  endoscopy  in  21  patients  with  BE  that  underwent
issen  fundoplication  with  follow-up.  The  authors  concluded
hat  ECE  appears  to  be  a  good  method  for  detecting  sus-
icious  esophageal  cancer  lesions  in  these  patients,  even
hough  it  had  modest  results  in  regard  to  the  precise  iden-
iﬁcation  of  BE  length  and  pattern.
We  ﬁnd  this  study  interesting  because  it  compares  ECE
ot  only  with  UGI  endoscopy,  but  also  with  MB  chromoen-
oscopy  -- a  magniﬁcation  method  of  greater  precision  in
esion  characterization.  This  study  design  has  not  been
ublished  before,  unquestionably  adding  to  the  study’s  orig-
nality.  However,  we  observed  a  number  of  limitations  that
e  feel  should  be  contemplated:
1)  The  ﬁnal  number  of  patients  included  in  the  study
(n  =  19)  is  low,  especially  when  taking  into  consideration
that  only  a  small  percentage  of  patients  with  BE  develop
adenocarcinoma  in  clinical  practice.  In  addition  only  one
patient  presented  with  lesions  suggestive  of  malignancy.
Therefore  any  conclusions  as  to  the  suitability  of  ECE  in
this  population  should  be  carefully  drawn.
2)  If  the  primary  objective  of  the  study  was  to  identify
patients  with  suspected  malignant  lesions,  then  the
grade  of  dysplasia  in  the  biopsy  specimens  should  have
been  shown,  given  that  this  is  currently  the  main  indi-
cator  for  determining  the  follow-up  and  time  between
endoscopies  in  these  patients.
. Published by Masson Doyma México S.A. All rights reserved.
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3)  In  the  study,  the  pattern  observed  through  UGI
endoscopy  with  MB  chromoendoscopy  is  regarded  as  the
gold  standard,  but  this  technique  is  not  reﬂected  as
such  in  published  studies  or  guidelines.  For  the  sake  of
greater  methodological  rigor,  the  histologic  study  of  the
biopsy  specimens  should  have  been  considered  as  this
standard.
4)  As  mentioned  before,  only  one  patient  had  suspected
malignant  lesions  after  UGI  endoscopy  and  chromoen-
doscopy.  However,  ECE  identiﬁed  4  suspicious  patients
and  regarded  them  as  false  positives,  suggesting  a  very
low  speciﬁcity  and  positive  predictive  value.
5)  As  observed  in  previous  studies,  ECE  cost-effectiveness
for  identifying  short  BE  is  limited  and  interobserver
concurrence  is  low.
As  the  authors  commented,  further  studies  on  a  large
umber  of  patients  (which  would  probably  be  possible  only
hrough  multicenter  studies)  are  deﬁnitely  necessary  in
rder  to  evaluate  the  true  role  of  ECE  in  patients  presenting
ith  BE.  Until  then,  UGI  endoscopy,  preferably  with  mag-
iﬁcation  techniques  and  the  histologic  study  of  the  biopsy
pecimens,  should  be  regarded  as  the  gold  standard  tech-
ique  in  these  patients.
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